Clinical Report: Infertility Treatment and Breast Cancer Risk in Women with BRCA Variants
Overview
This study investigates the association between infertility treatment and breast cancer risk among women with BRCA pathogenic variants. The findings indicate no significant increase in breast cancer risk related to infertility treatment or fertility medications in this high-risk population.
Background
Women with BRCA1 or BRCA2 pathogenic variants face elevated risks for breast and ovarian cancers, complicating family planning decisions. As infertility treatments become more common, understanding their potential impact on cancer risk is crucial for informed patient care. Previous studies have shown mixed results regarding the relationship between fertility treatments and breast cancer risk in the general population, necessitating further investigation specifically in BRCA carriers.
Data Highlights
No significant association was found between infertility treatment and breast cancer risk among BRCA pathogenic variant carriers.
Key Findings
No increased breast cancer risk was associated with a history of infertility among BRCA carriers.
Fertility medications, including gonadotropins and SERMs, did not correlate with heightened breast cancer risk.
In vitro fertilization (IVF) treatment showed no significant link to breast cancer incidence in this cohort.
Findings support previous research indicating that infertility treatment does not materially modify breast cancer risk in BRCA carriers.
Current guidelines from ASRM and ASCO reinforce the safety of fertility treatments in this population.
Clinical Implications
Healthcare providers can reassure BRCA carriers that infertility treatments, including IVF and fertility medications, do not appear to increase breast cancer risk. This information is vital for guiding family planning and fertility preservation discussions in this high-risk group.
Conclusion
The study provides important evidence that infertility treatment does not significantly affect breast cancer risk in women with BRCA pathogenic variants, supporting the safety of these interventions in clinical practice.
by Marta Seca, Jacek Gronwald, Tomasz Huzarski, Karen Glass, Amber Aeilts, Raymond H. Kim, Beth Karlan, Christian F. Singer, Andrea Eisen, Nadine Tung, Olufunmilayo Olopade, Louise Bordeleau, Pal Moller, William D. Foulkes, Susan L. Neuhausen, Fergus Couch, Tuya Pal, Robert Fruscio, Cezary Cybulski, Jan Lubinski, Shana Kim, Ping Sun, Steven A. Narod, Joanne Kotsopoulos
Sexual dysfunction is a lasting effect of treatment and can impact the quality of life of breast cancer survivors. This review examined the impact of different levels (none/low, moderate, and high) of physical activity on sexual outcomes in breast cancer survivors.
